Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection

Pharmacol Res. 2020 Jul:157:104837. doi: 10.1016/j.phrs.2020.104837. Epub 2020 Apr 22.

Authors

Roberto Maggio¹, Giovanni U Corsini²

Affiliations

¹ Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy. Electronic address: roberto.maggio@univaq.it.
² Former Professor of Pharmacology, School of Medicine, University of Pisa, Italy. Electronic address: gucorsini@tiscali.it.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antitussive Agents*
Betacoronavirus
Bromhexine*
COVID-19
Coronavirus Infections
Expectorants
Humans
Pandemics
Peptidyl-Dipeptidase A
Pneumonia, Viral
Protease Inhibitors
SARS-CoV-2
Severe acute respiratory syndrome-related coronavirus*
Virus Internalization

Substances

Antitussive Agents
Expectorants
Protease Inhibitors
Peptidyl-Dipeptidase A
Bromhexine